A measurable GH response
A controlled human study characterised intravenous ipamorelin disposition and GH release. It did not test consumer body-composition or recovery claims. [1]
Compound evidence dossier · C-016
Ipamorelin: growth-hormone claims and evidence
A ghrelin-receptor agonist promoted as a selective growth-hormone secretagogue. Human outcome evidence does not support the recovery and body-composition promises.
What does the evidence say?
Ipamorelin can trigger growth-hormone release, but human trials have not shown the muscle, fat-loss, recovery, sleep or anti-ageing benefits used to market it. “Selective” describes a pharmacology claim, not a proven clinical advantage. The largest identifiable therapeutic trial, in postoperative ileus, did not meet its efficacy endpoint and used intravenous dosing in a hospital population.
Claim check
Which claims survive an evidence check?
Each row keeps the claim, its best supporting evidence and the limiting caveat together.
Selectively releases growth hormoneMechanism supported
Early laboratory and animal work described relative selectivity at tested conditions. Human pharmacology shows GH release. Neither point establishes superior outcomes or a clean long-term safety profile in people.
Improves recovery or body compositionNot demonstrated
No reliable human trials establish the marketed recovery, muscle-gain or fat-loss outcomes. Hormone release is an intermediate endpoint and cannot substitute for those results.
Improves gut recovery after surgeryTrial negative
Safer than older GHRPsUnresolved
Selectivity claims do not provide comparative long-term safety evidence. The relevant trials do not establish that online injectable use is safer than GHRP-2, GHRP-6 or hexarelin.
Human evidence
What have studies in people shown?
Human studies establish pharmacokinetics and a GH response. The only substantial clinical programme identified for a therapeutic outcome tested a different indication, route and setting, and failed on efficacy.
Postoperative ileus result
The phase II trial did not shorten time to the first meal or show the intended improvement in gastrointestinal recovery. [2]
Route and setting matter
The FDA identified hypokalaemia, insomnia, hyperglycaemia, nausea, vomiting and abdominal distension in the intravenous programme. Two deaths occurred, with causal relationship unclear. Those data do not quantify risk from other injectable routes. [3]
Critical distinction
What “selective” means, and what it does not mean
A selective receptor response can make a compound interesting to researchers. It cannot answer whether a person gains useful benefit with acceptable harm.
- Mechanism
- Ipamorelin is a ghrelin-receptor agonist and GH secretagogue. This differs from CJC-1295, which acts as a GHRH analogue.
- Selectivity evidence
- The often-cited selectivity paper was preclinical. Results from cells or animals do not prove endocrine selectivity in long-term human use.
- Outcome evidence
- No dependable human evidence establishes the common physique, recovery, sleep or longevity claims.
- Comparison limit
- No sound head-to-head programme establishes that ipamorelin is safer or more effective than the older secretagogues sold beside it.
Risk register
What could go wrong?
Known trial events, a poorly characterised market product and missing route-specific safety data each matter. They should not be blended into one vague warning.
| Risk channel | Evidence-aware interpretation |
|---|---|
| Observed in a clinical programme | Metabolic, sleep and gastrointestinal adverse events were reported. Two deaths occurred; their relationship to ipamorelin was not established. |
| Mechanism-linked | GH and IGF-1 changes may affect glucose regulation and fluid balance. The probability and severity for non-authorised use are not known. |
| Product quality | The FDA flags aggregation, peptide-related impurities and characterisation complexity, including the presence of unnatural amino acids. |
| Evidence gap | There is no adequate safety dataset for the subcutaneous products and patterns of use promoted online. |
Product evidence
What would evidence about a vial prove?
A compound-level literature verdict and a product-level finding answer different questions. Neither can substitute for the other.
Claimed compound
The literature applies only if the vial contains the same active substance and form that the source studied.
Label and release record
A batch-specific record should identify the material, method, result, specification and accountable laboratory.
Submitted sample
A defensible result concerns the sample tested. It does not certify every vial, future batch or storage condition.
Clinical meaning
Identity, purity and sterility evidence cannot establish a health outcome or fill a missing human safety dataset.
Status check
Is it authorised or prohibited?
Medicine authorisation, lawful supply and anti-doping status are separate checks. Each can change and should be verified at the point of decision.
| System | Finding checked 8 August 2026 |
|---|---|
| UK medicine status | No ipamorelin medicine with a UK marketing authorisation was identified in the MHRA public database check. |
| United States | Ipamorelin is not an FDA-approved drug component. The FDA advisory review found insufficient effectiveness evidence and important safety gaps for nominated uses and routes. |
| Sport | Ipamorelin is named as a prohibited growth-hormone secretagogue on the 2026 WADA list. The prohibition applies at all times. |
Method note
How was this judgement made?
We separated the original preclinical selectivity claim, the human pharmacology study and the failed postoperative clinical programme. Findings were not transferred across routes or populations without a caveat.
Searches prioritised regulator documents, current medicine and anti-doping records, trial registrations and indexed primary studies. Seller pages were not used as evidence of efficacy or safety.
Read the full editorial method and inspect the evidence library.
Source ledger
Primary sources
- Raun et al., pharmacokinetic and pharmacodynamic properties of ipamorelinHuman pharmacology; not an advertised-outcome trial. Checked 8 August 2026.
- Phase II trial of ipamorelin for postoperative ileusRandomised clinical trial; efficacy endpoint not met. Checked 8 August 2026.
- US FDA, Ipamorelin Pharmacy Compounding Advisory Committee briefingRegulatory evidence and safety review, including route-specific limitations. Checked 8 August 2026.
- Raun et al., original selectivity studyPreclinical evidence; not proof of human outcomes. Checked 8 August 2026.
- US FDA, Certain Bulk Drug Substances That May Present Significant Safety RisksCurrent regulator summary of characterisation, impurity, immunogenicity and safety concerns. Checked 8 August 2026.
- World Anti-Doping Agency, 2026 Prohibited ListCurrent list used for sport-status checks; effective 1 January 2026. Checked 8 August 2026.
- MHRA ProductsPublic UK medicines database used for the marketing-authorisation check. Checked 8 August 2026.
Questions answered
Frequently asked questions
Short answers keep the decisive caveat beside the claim.
Is ipamorelin a medicine in the UK?
No UK-authorised ipamorelin medicine was identified in the MHRA public database check. A product described as compounded or research-grade does not gain a UK marketing authorisation through that label.
Is ipamorelin proven to build muscle?
No reliable human trial evidence establishes muscle gain from ipamorelin. A growth-hormone response is a biological signal, not a demonstrated body-composition outcome.
What does selective mean here?
It refers to the pattern of hormone release or receptor activity under tested conditions. The prominent early selectivity evidence was preclinical, and the term does not prove better results or fewer harms in long-term human use.
Did people die in an ipamorelin trial?
Two deaths occurred in an intravenous postoperative trial. The FDA review states that the causal relationship was unclear. This is a safety signal that needs context, not proof that ipamorelin caused each death.
Is ipamorelin prohibited in sport?
Yes. Ipamorelin is named in the 2026 WADA list among growth-hormone secretagogues and is prohibited at all times. Athletes should verify their exact circumstances with their anti-doping organisation.
Can online product testing settle the clinical risk?
No. Good testing can support the identity, purity or sterility of the submitted sample when suitable methods are used. It cannot supply missing long-term human safety or efficacy evidence.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Claim-level recordDoes ipamorelin trigger growth-hormone release?Read the verdict, confidence, sources and scope limits.Claim-level recordDoes ipamorelin improve recovery or body composition?Read the verdict, confidence, sources and scope limits.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item C-016, Ipamorelin: growth-hormone claims and evidence was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 7 unique external sources and 11 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.